EKSO BIONICS, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on the stock and has a $4.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Swayampakula Ramakanth has given his Buy rating due to a combination of factors that highlight both challenges and potential growth for Ekso Bionics. Despite a notable decline in enterprise revenue, attributed to unexpected order delays, the analyst remains optimistic about the company’s long-term prospects. The delays, which affected significant orders from North American and Asia Pacific customers, are seen as isolated incidents that are not expected to impact the company’s growth trajectory significantly.
Moreover, the progress in the distribution of the Ekso Indego Personal device, particularly through partnerships with National Seating and Mobility and Bionic Prosthetics & Orthotics Group, is encouraging. These partnerships have expanded the pipeline of potential customers, with an increase in identified Medicare beneficiaries who are candidates for the device. The analyst also notes that the company’s financial position, with sufficient cash reserves, supports operations into the first quarter of 2026, and the valuation methods used suggest a favorable price target, reinforcing the Buy rating.
Ramakanth covers the Healthcare sector, focusing on stocks such as Ocugen, Delcath Systems, and Corcept Therapeutics. According to TipRanks, Ramakanth has an average return of 6.8% and a 38.72% success rate on recommended stocks.
In another report released on July 29, Lake Street also maintained a Buy rating on the stock with a $9.50 price target.